

Cover Story
FreeGuest Editorial
The ever-rising cost of oncology drugs is doing damage to cancer care on many levels.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Backlog of work grows at NIH as staff members are being hounded to quit
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- In the Headlines: Could “flooding the zone” drown NIH and cancer centers?
- In the Headlines: What are Jay Bhattacharya’s plans for NIH?
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers